Literature DB >> 26135252

Treatment and Management of Dementia Due to Alzheimer's Disease.

Jennifer Rose V Molano1, Robin Bratt, Rhonna Shatz.   

Abstract

OPINION STATEMENT: Alzheimer's disease (AD) is a progressive neurological disorder typically associated with episodic memory loss as the initial symptom, but individuals <65 years old may present with executive dysfunction, word finding difficulties, or visual processing deficits. In those with AD, curative treatments are not available, but there are interventions which may modify disease course, symptom appearance and severity, enhance quality of life for patient and caregivers, and maintain safety. Both pharmacological and non-pharmacological interventions are important.

Entities:  

Year:  2015        PMID: 26135252     DOI: 10.1007/s11940-015-0363-4

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  51 in total

1.  Quality improvement in neurology: dementia management quality measures.

Authors:  Germaine Odenheimer; Soo Borson; Amy E Sanders; Rebecca J Swain-Eng; Helen H Kyomen; Samantha Tierney; Laura N Gitlin; Mary Ann Forciea; John Absher; Joseph Shega; Jerry Johnson
Journal:  Neurology       Date:  2013-09-25       Impact factor: 9.910

Review 2.  The evaluation and management of the acutely agitated elderly patient.

Authors:  Denise Nassisi; Beatriz Korc; Sigrid Hahn; John Bruns; Andy Jagoda
Journal:  Mt Sinai J Med       Date:  2006-11

3.  Depression in dementia: epidemiology, mechanisms, and treatment.

Authors:  Daniela Enache; Bengt Winblad; Dag Aarsland
Journal:  Curr Opin Psychiatry       Date:  2011-11       Impact factor: 4.741

4.  Burden of Behavioral and Psychiatric Symptoms in People Screened Positive for Dementia in Primary Care: Results of the DelpHi-Study.

Authors:  Jochen René Thyrian; Tilly Eichler; Johannes Hertel; Diana Wucherer; Adina Dreier; Bernhard Michalowsky; Ingo Killimann; Stefan Teipel; Wolfgang Hoffmann
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

5.  Update on the pharmacological treatment of Alzheimer's disease.

Authors:  Fadi Massoud; Serge Gauthier
Journal:  Curr Neuropharmacol       Date:  2010-03       Impact factor: 7.363

6.  The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia.

Authors:  J L Cummings; M Mega; K Gray; S Rosenberg-Thompson; D A Carusi; J Gornbein
Journal:  Neurology       Date:  1994-12       Impact factor: 9.910

7.  Treatment of a whole population sample of Alzheimer's disease with donepezil over a 4-year period: lessons learned.

Authors:  Sarah Lyle; Moni Grizzell; Sasi Willmott; Susan Benbow; Michael Clark; David Jolley
Journal:  Dement Geriatr Cogn Disord       Date:  2008-01-30       Impact factor: 2.959

Review 8.  Sleep and neurodegenerative diseases.

Authors:  Sudhansu Chokroverty
Journal:  Semin Neurol       Date:  2009-09-09       Impact factor: 3.420

Review 9.  Practice parameter update: evaluation and management of driving risk in dementia: report of the Quality Standards Subcommittee of the American Academy of Neurology.

Authors:  D J Iverson; G S Gronseth; M A Reger; S Classen; R M Dubinsky; M Rizzo
Journal:  Neurology       Date:  2010-04-12       Impact factor: 11.800

10.  Use of physical and intellectual activities and socialization in the management of cognitive decline of aging and in dementia: a review.

Authors:  Myuri Ruthirakuhan; Angela C Luedke; Angela Tam; Ankita Goel; Ayaz Kurji; Angeles Garcia
Journal:  J Aging Res       Date:  2012-12-31
View more
  2 in total

1.  Combining Chalcones with Donepezil to Inhibit Both Cholinesterases and Aβ Fibril Assembly.

Authors:  Nishad Thamban Chandrika; Marina Y Fosso; Oleg V Tsodikov; Harry LeVine Iii; Sylvie Garneau-Tsodikova
Journal:  Molecules       Date:  2019-12-24       Impact factor: 4.411

2.  Prescribing medications of questionable benefit prior to death: a retrospective study on older nursing home residents with and without dementia in Germany.

Authors:  Christian Rausch; Falk Hoffmann
Journal:  Eur J Clin Pharmacol       Date:  2020-03-26       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.